The CDC updated and simplified its vaccine recommendations on April 19, 2023, and the Moderna and Pfizer-BioNTech mRNA bivalent COVID-19 vaccines should be used for all vaccinations in the US.
This article first appeared on our sister brand, Contagionlive.com.
Following the US Food and Drug Administration (FDA) authorization on April 18, 2023, the US Centers for Disease Control and Prevention (CDC) has significantly changed its COVID-19 vaccine recommendations.
The most significant update is that the FDA and CDC now recommend that the Moderna and Pfizer-BioNTech mRNA bivalent mRNA vaccines (original and Omicron BA.4/BA.5 strains) be used for all future vaccinations in the US. This means both agencies are officially moving away from the initial, monovalent COVID-19 vaccines.
The CDC now recommends:
Immunocompromised individuals may be eligible to receive additional doses of a bivalent vaccine, even if they have already. Individuals with comorbidities or otherwise immunocompromised should consult a health care provider to determine their needs and ensure they can mount an adequate immune response to vaccination.
The new regulations were announced tonight, April 19, after the CDC’s Advisory Committee on Immunization Practices (ACIP) met to discuss these changes to their COVID-19 vaccine recommendation.
Most individuals who have already received a single dose of the bivalent Pfizer-BioNTech or Moderna booster are only eligible for another dose if they are immunocompromised or 65 years and older. The FDA will likely announce future vaccination recommendations after determining fall’s vaccine strain composition in their June advisory meeting.
Alternative options are still available for individuals unable to receive an updated bivalent COVID-19 vaccine. Today's decision did not affect the CDC’s recommendation of the (monovalent) Novavax or Johnson & Johnson’s Janssen COVID-19 vaccines.
Keep up with COVID-19 on Infection Control Today®.
Tracking Pathogen Contamination in a New Children’s Outpatient Pulmonary Clinic
June 17th 2024A study at the 2024 APIC conference observed MRSA and Pseudomonas contamination in a new children's outpatient pulmonary clinic during construction and after patient use, highlighting significant infection risks.
Our Understanding of Immune Issues Is Evolving: Here Are 5 Reasons Why
June 14th 2024Recent medical advances include RNA vaccine technology, enhanced understanding of immune dysregulation, improved inter-specialty communication, deeper insights into inflammation, and recognition of biological complexity.
Strategies to Prevent Infection During Childbirth: Vaginal vs Cesarean Delivery
June 13th 2024Infection prevention during childbirth, via vaginal or cesarean delivery, is crucial for maternal and neonatal health. Strategies include strict hygiene, sterile techniques, and antibiotic prophylaxis to reduce postpartum infection risks.
Standardizing Cleaning Protocols Across the Care Continuum
June 12th 2024Brooke Hossfeld MPH, CIC, MLS (ASCP)CM presented the need for standardized infection prevention protocols across health care settings, addressing challenges from retiring workers to HAIs infections in outpatient facilities at APIC24.